One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study. These data were publi ...

50% LDL-C reduction from baseline and the new lower LDL-C target of < 55 mg/dL for those with, or at very hisk for, CVD Lerodalcibep reduced mean Apo B by 45% and median Lp(a) by 30-32% Lerodalcibep ...

The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay. Specifically, the reductions were 47.6% at 10 mg, 81.7% at 60 mg and 85.8% at 240 mg ...

Mulvalaplin works, Nicholls explained at the press briefing, by disrupting the bonding of apo(a) to apoB, which does not allow Lp(a) to form. The study examined 3 different doses, at 10 mg, 60 mg and ...

This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high ...

This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept ... (T1), the three groups exhibited decreases of 33.49±10.80 mm Hg, 36 ...

Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and ...

Man Suang premiered on 21 August 2023, marking Apo’s film debut. The movie, set in 1850s Siam, tells the tale of two performers who risk their lives to infiltrate an elite social club and unmask ...